ESTRO 2025 - Abstract Book

S1072

Clinical – Head & neck

ESTRO 2025

The study recruited 150 people with p16+ve disease with a median follow-up of 13.8 months. 120 people were suitable for analysis due to study withdrawals and/or incomplete samples/imaging. Of these 112/120 were confirmed as HPV+ve by RNA/DNA PCR. The assay demonstrated a sensitivity of 86% (112/131; 95% CI:78 – 91) and specificity of 92% (12/13; 95% CI: 64 – 100) at baseline. 97/112 people with HPV+ve disease had detectable cHPV-DNA at baseline, 11-20 week plasma samples and 18F-FDG PET-CT available. The specificity of HPV-detect at 3 months was 88% (95% CI: 76 – 95), increasing to 90% (95% CI:81 – 96) when repeat 18F-FDG-PET-CT imaging was incorporated (primary endpoint). Among the 70 people with a negative 18F-FDG-PET-CT, 7 had positive HPV-detect, with 3 of these developing recurrence. Of the 6 people with negative HPV detect result, 2 had confirmed recurrent/residual disease.

An exploratory analysis of HPV-detect concordance at 3 months with overall disease status is shown in Table 1.

Conclusion: Preliminary results of our NGS-based assay for detecting cHPV-DNA demonstrate high sensitivity and specificity at baseline and high specificity but sub-optimal sensitivity compared to 18F-FDG-PET-CT at 3 months post-CRT. However, the low number of patients with residual or recurrent disease limits the study’s power to draw definitive conclusions regarding sensitivity.

Keywords: plasma HPV-DNA, Radical CRT, Response assessment

References: Lee, J.Y., et al., Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. Br J Cancer, 2017. 117 (6): p. 876-883.

3234

Digital Poster Research on the application of Raman spectroscopy in predicting the efficacy of nasopharyngeal carcinoma treatment and assessing adverse reactions Rui Huang 1 , Hua Fan 1,2 , Yilin Yang 1,2 , Jinyi Lang 1 , Peng Zhang 1 1 Department of Radiation Oncology, Sichuan Cancer Hospital and Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation oncology Key Laboratory of Sichuan Province, Chengdu, China. 2 Graduate School, Chengdu Medical College, Chengdu, China Purpose/Objective: This study applied Raman spectroscopy to detect serum samples from nasopharyngeal carcinoma (NPC) patients and explore the differences in serum Raman spectroscopy with different efficacy and acute adverse reactions.